Cassava up; co expects late-stage trial data for Alzheimer's drug in December

Filana Therapeutics

22/07/2024 13:30

** Shares of drug developer Cassava Sciences  SAVA.O  rise
~4.2% to $10.50 premarket
    ** Co says it is expecting data from the first late-stage
trial of its Alzheimer's drug simufilam in December
    ** Adds, second late-stage trial evaluating the drug will
conclude by June 2025
    ** Up to last close, stock down 55.2% YTD

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))